AbCellera has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets. Lilly will have the rights to develop and commercialize therapeutic products resulting from the collaboration.
AbCellera and Lilly were in discussions about the multi- target agreement in early 2020 when the COVID-19 pandemic emerged. The companies worked quickly to focus the initial scope of the collaboration on creating antibody therapeutics for the possible prevention and treatment of COVID-19. Lilly will select up to eight additional targets during the multi-year agreement.
aLilly chose to partner with AbCellera because of their novel technology platform, and it has enabled the rapid identification of lead antibody candidates for our COVID-19 efforts. Weare excited to now apply it to other therapeutic targets,a said Daniel Skovronsky, M.D., Ph.D., Lillyas chief scientific officer and president of Lilly Research Laboratories. aAbCelleraas capabilities and team are extremely impressive and we are proud of the progress weave made together thus far.a
Applying best-in-class technology and custom innovation to each project, AbCellera partners with leading pharma and biotech to enable programs for any target class. With more than 55 successfully completed programs, AbCellera is transforming the field of biologics by reducing the time it takes to identify lead candidates and advance new products towards the clinic.
aBy working together seamlessly, our teams...